Search Results
Search for other papers by E Baudin in
Google Scholar
PubMed
Search for other papers by J Capdevila in
Google Scholar
PubMed
Search for other papers by D Hörsch in
Google Scholar
PubMed
Search for other papers by S Singh in
Google Scholar
PubMed
Search for other papers by M E Caplin in
Google Scholar
PubMed
Search for other papers by E M Wolin in
Google Scholar
PubMed
Search for other papers by W Buikhuisen in
Google Scholar
PubMed
Search for other papers by M Raderer in
Google Scholar
PubMed
Search for other papers by E Dansin in
Google Scholar
PubMed
Search for other papers by C Grohe in
Google Scholar
PubMed
Search for other papers by D Ferone in
Google Scholar
PubMed
Search for other papers by A Houchard in
Google Scholar
PubMed
Search for other papers by X-M Truong-Thanh in
Google Scholar
PubMed
Search for other papers by D Reidy-Lagunes in
Google Scholar
PubMed
Search for other papers by the SPINET Study Group in
Google Scholar
PubMed
gastrointestinal NETs: lanreotide autogel/depot (LAN) in patients with slowly progressive well- or moderately differentiated gastroenteropancreatic (GEP) NETs ( Caplin et al. 2014 ), and octreotide long-acting release (OCT) in patients with well
Search for other papers by Martyn E Caplin in
Google Scholar
PubMed
Search for other papers by Marianne Pavel in
Google Scholar
PubMed
Search for other papers by Jarosław B Ćwikła in
Google Scholar
PubMed
Search for other papers by Alexandria T Phan in
Google Scholar
PubMed
Search for other papers by Markus Raderer in
Google Scholar
PubMed
Search for other papers by Eva Sedláčková in
Google Scholar
PubMed
Search for other papers by Guillaume Cadiot in
Google Scholar
PubMed
Search for other papers by Edward M Wolin in
Google Scholar
PubMed
Search for other papers by Jaume Capdevila in
Google Scholar
PubMed
Search for other papers by Lucy Wall in
Google Scholar
PubMed
Search for other papers by Guido Rindi in
Google Scholar
PubMed
Search for other papers by Alison Langley in
Google Scholar
PubMed
Search for other papers by Séverine Martinez in
Google Scholar
PubMed
Search for other papers by Edda Gomez-Panzani in
Google Scholar
PubMed
Royal Free Hospital, Charité University Medicine Berlin, University of Warmia and Mazury, University of Texas MD Anderson Cancer Center, University Hospital, Department of Oncology of the First Faculty of Medicine and General Teaching Hospital, Robert‐Debré Hospital, Markey Cancer Center, Vall d'Hebron University Hospital, Western General Hospital, Università Cattolica del Sacro Cuore, Ipsen, Ipsen, Beaujon Hospital, Paris Diderot University, London, UK
Search for other papers by Philippe Ruszniewski in
Google Scholar
PubMed
Search for other papers by on behalf of the CLARINET Investigators in
Google Scholar
PubMed
Introduction CLARINET was a landmark 96-week study that confirmed anti-tumour effects for the long-acting somatostatin analogue lanreotide Autogel (depot in the USA) 120 mg. Lanreotide prolonged progression-free survival (PFS) over placebo in
Search for other papers by Jonathan R Strosberg in
Google Scholar
PubMed
Search for other papers by James C Yao in
Google Scholar
PubMed
Search for other papers by Emilio Bajetta in
Google Scholar
PubMed
Search for other papers by Mounir Aout in
Google Scholar
PubMed
Search for other papers by Bert Bakker in
Google Scholar
PubMed
Search for other papers by John D Hainsworth in
Google Scholar
PubMed
Search for other papers by Philippe B Ruszniewski in
Google Scholar
PubMed
Search for other papers by Eric Van Cutsem in
Google Scholar
PubMed
Search for other papers by Kjell Öberg in
Google Scholar
PubMed
Search for other papers by Marianne E Pavel in
Google Scholar
PubMed
), patients with advanced NET treated with lanreotide autogel (120 mg via deep s.c. injection every 28 days) also had improvement in progression-free survival (PFS) when compared with placebo (PFS, not reached (NR) vs 18 months and HR, 0.47; 95% Cl 0
Search for other papers by Kjell Öberg in
Google Scholar
PubMed
Search for other papers by Steven W J Lamberts in
Google Scholar
PubMed
lanreotide Autogel, the first available sustained-release formulation based on self-assembling nanotube technology ( Fig. 1 ) ( Pouget et al . 2010 ). After administration, lanreotide peptide monomers are slowly released from the ends of the nanotubes over a
Search for other papers by Iulia Potorac in
Google Scholar
PubMed
Search for other papers by Patrick Petrossians in
Google Scholar
PubMed
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by Orsalia Alexopoulou in
Google Scholar
PubMed
Search for other papers by Sophie Borot in
Google Scholar
PubMed
Search for other papers by Mona Sahnoun-Fathallah in
Google Scholar
PubMed
Search for other papers by Frederic Castinetti in
Google Scholar
PubMed
Search for other papers by France Devuyst in
Google Scholar
PubMed
Search for other papers by Marie-Lise Jaffrain-Rea in
Google Scholar
PubMed
Search for other papers by Claire Briet in
Google Scholar
PubMed
Search for other papers by Florina Luca in
Google Scholar
PubMed
Search for other papers by Marion Lapoirie in
Google Scholar
PubMed
Search for other papers by Flavius Zoicas in
Google Scholar
PubMed
Search for other papers by Isabelle Simoneau in
Google Scholar
PubMed
Search for other papers by Alpha M Diallo in
Google Scholar
PubMed
Search for other papers by Ammar Muhammad in
Google Scholar
PubMed
Search for other papers by Fahrettin Kelestimur in
Google Scholar
PubMed
Search for other papers by Elena Nazzari in
Google Scholar
PubMed
Search for other papers by Rogelio Garcia Centeno in
Google Scholar
PubMed
Search for other papers by Susan M Webb in
Google Scholar
PubMed
Search for other papers by Marie-Laure Nunes in
Google Scholar
PubMed
Search for other papers by Vaclav Hana in
Google Scholar
PubMed
Search for other papers by Véronique Pascal-Vigneron in
Google Scholar
PubMed
Search for other papers by Irena Ilovayskaya in
Google Scholar
PubMed
Search for other papers by Farida Nasybullina in
Google Scholar
PubMed
Search for other papers by Samia Achir in
Google Scholar
PubMed
Search for other papers by Diego Ferone in
Google Scholar
PubMed
Search for other papers by Sebastian J C M M Neggers in
Google Scholar
PubMed
Search for other papers by Brigitte Delemer in
Google Scholar
PubMed
Search for other papers by Jean-Michel Petit in
Google Scholar
PubMed
Search for other papers by Christof Schöfl in
Google Scholar
PubMed
Search for other papers by Gerald Raverot in
Google Scholar
PubMed
Search for other papers by Bernard Goichot in
Google Scholar
PubMed
Search for other papers by Patrice Rodien in
Google Scholar
PubMed
Search for other papers by Bernard Corvilain in
Google Scholar
PubMed
Search for other papers by Thierry Brue in
Google Scholar
PubMed
Search for other papers by Franck Schillo in
Google Scholar
PubMed
Search for other papers by Luaba Tshibanda in
Google Scholar
PubMed
Search for other papers by Dominique Maiter in
Google Scholar
PubMed
Search for other papers by Jean-François Bonneville in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
received lanreotide Autogel (among these, one was switched to octreotide LAR), 69 patients received octreotide LAR (among them, two were switched to lanreotide Autogel) and three received pasireotide. For three patients, the SSA dose used was unknown. The
Department of Oncology, Ryhov County Hospital, Jönköping, Sweden
Search for other papers by Dimitrios Papantoniou in
Google Scholar
PubMed
Search for other papers by Malin Grönberg in
Google Scholar
PubMed
Search for other papers by Espen Thiis-Evensen in
Google Scholar
PubMed
University of Bergen, Deptartment of Clinical Medicine, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Department of Surgery, Ryhov County Hospital, Jönköping, Sweden
Search for other papers by Kalle Landerholm in
Google Scholar
PubMed
Search for other papers by Staffan Welin in
Google Scholar
PubMed
Search for other papers by Eva Tiensuu Janson in
Google Scholar
PubMed
2014 , Lamberti et al. 2020 , Diamantopoulos et al. 2021 ). A prospective phase 2 trial (CLARINET FORTE) with above-label dose of lanreotide autogel recently reported moderate efficacy, with a median PFS of 8.3 months in the Si-NET subgroup. Only
Search for other papers by Johannes Hofland in
Google Scholar
PubMed
Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain
Endocrinology and Nutrition Service, Reina Sofia University Hospital, Córdoba, Spain
Search for other papers by Aura D Herrera-Martínez in
Google Scholar
PubMed
Search for other papers by Wouter T Zandee in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
-blind placebo-controlled trials studying the antiproliferative effects of octreotide LAR and lanreotide autogel led to the world-wide registration of these drugs as antiproliferative agents in NET patients. However, the PROMID study ( Rinke et al. 2009
Search for other papers by Louis de Mestier in
Google Scholar
PubMed
Search for other papers by Angela Lamarca in
Google Scholar
PubMed
Search for other papers by Jorge Hernando in
Google Scholar
PubMed
Division of Endocrinology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Search for other papers by Wouter Zandee in
Google Scholar
PubMed
Search for other papers by Teresa Alonso-Gordoa in
Google Scholar
PubMed
Search for other papers by Marine Perrier in
Google Scholar
PubMed
Search for other papers by Annemiek ME Walenkamp in
Google Scholar
PubMed
Search for other papers by Bipasha Chakrabarty in
Google Scholar
PubMed
Search for other papers by Stefania Landolfi in
Google Scholar
PubMed
Search for other papers by Marie-Louise F Van Velthuysen in
Google Scholar
PubMed
Search for other papers by Gursah Kats-Ugurlu in
Google Scholar
PubMed
Search for other papers by Alejandra Caminoa in
Google Scholar
PubMed
Search for other papers by Maxime Ronot in
Google Scholar
PubMed
Search for other papers by Prakash Manoharan in
Google Scholar
PubMed
Search for other papers by Alejandro Garcia-Alvarez in
Google Scholar
PubMed
Search for other papers by Tessa Brabander in
Google Scholar
PubMed
Search for other papers by María Isabel García Gómez-Muriel in
Google Scholar
PubMed
Search for other papers by Guillaume Cadiot in
Google Scholar
PubMed
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Search for other papers by Jaume Capdevila in
Google Scholar
PubMed
Search for other papers by Marianne E Pavel in
Google Scholar
PubMed
Search for other papers by Jérôme Cros in
Google Scholar
PubMed
collected, as well as follow-up data. Treatments were regrouped as alkylating-based CT (temozolomide-, dacarbazine- or streptozotocin-based), etoposide-platinum CT, adenocarcinoma-like CT (FOLFOX- or FOLFIRI-based), somatostatin analogs (lanreotide autogel
Search for other papers by M C F Mulders in
Google Scholar
PubMed
Search for other papers by Q G de Lussanet de la Sablonière in
Google Scholar
PubMed
Search for other papers by M L F van Velthuysen in
Google Scholar
PubMed
Search for other papers by E M Roes in
Google Scholar
PubMed
Search for other papers by J Hofland in
Google Scholar
PubMed
Search for other papers by W W de Herder in
Google Scholar
PubMed
). Regarding patients on SSA treatment, only those on a stable dose of either octreotide LAR (30 mg/4 weeks) or lanreotide autogel (120 mg/4 weeks) were selected for TGR analysis. Statistics Data are presented as mean ± s.d. for normally distributed
Search for other papers by Benjamin Easton White in
Google Scholar
PubMed
Search for other papers by Maralyn R Druce in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
Search for other papers by Rajaventhan Srirajaskanthan in
Google Scholar
PubMed
Search for other papers by Eva Maria Gamper in
Google Scholar
PubMed
Search for other papers by Debra Gray in
Google Scholar
PubMed
Search for other papers by Ruben Mujica-Mota in
Google Scholar
PubMed
King’s Health Partners ENETS Centre of Excellence, Kings College hospital, London, UK
Search for other papers by John K Ramage in
Google Scholar
PubMed
Molecular Imaging 46 2252 – 2259 . ( https://doi.org/10.1007/s00259-019-04431-3 ) Martín-Richard M Massutí B Pineda E Alonso V Marmol M Castellano D 2013 Antiproliferative effects of lanreotide autogel in patients with progressive, well